Leveraging the experience of founder and Chief Executive Officer Randall Fincke, Access CardioSystems, an innovator and developer of defibrillation technology, grew into a company with more than 75 employees and worldwide sales in the thousands of units. Its products included the AccessAED, a defibrillator with proprietary technology and other clinical advantages over its competitors. The United States Food and Drug Administration approved the device in August of 2002, including ISO certification and CE mark regulatory approval. Access CardioSystems brought its offerings to market with the help of international distribution partners located in more than 50 nations.
In 2002, when Access CardioSystems defibrillators first entered the market, the product played a key role in thousands of rescue operations and produced an industry leading quality record and a high standard of reliability. In fact, a clinical study sanctioned by the company revealed the proprietary Biphasic WaveControl used by such products as the AccessAED resulted in a 100 percent first-shock success rate in defibrillating patients. The findings, presented at the American College of Cardiology's Annual Scientific Session, also recorded no adverse effects occurred following defibrillation by the AccessAED.
Following his time at Access CardioSystems, Randall Fincke established Advent Medical Products, a company specializing in clinician and patient mobility, advanced clinical treatment, and wireless capabilities.